Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT.

Blood. 2006 Mar 15;107(6):2279-85. Epub 2005 Nov 15.

2.

Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Kato GJ, Gladwin MT.

JAMA. 2008 Dec 10;300(22):2638-46. doi: 10.1001/jama.2008.598. Review.

3.

Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain.

Taylor JG 6th, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT, Steinberg MH.

PLoS One. 2008 May 7;3(5):e2095. doi: 10.1371/journal.pone.0002095.

4.

Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.

Morris CR, Kato GJ, Poljakovic M, Wang X, Blackwelder WC, Sachdev V, Hazen SL, Vichinsky EP, Morris SM Jr, Gladwin MT.

JAMA. 2005 Jul 6;294(1):81-90.

5.

Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.

Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT.

Blood. 2007 Apr 1;109(7):3088-98. Erratum in: Blood. 2008 Feb 15;111(4):1772.

6.

Degree of anemia, indirect markers of hemolysis, and vascular complications of sickle cell disease in Africa.

Dubert M, Elion J, Tolo A, Diallo DA, Diop S, Diagne I, Sanogo I, Belinga S, Guifo O, Wamba G, Ngo Sack F, Boidy K, Kamara I, Traore Y, Diakite CO, Gbonon V, Faye BF, Seck M, Deme Ly I, Chelo D, N'Guetta R, Diop IB, Gaye B, Jouven X, Ranque B.

Blood. 2017 Nov 16;130(20):2215-2223. doi: 10.1182/blood-2016-12-755777. Epub 2017 Sep 20.

PMID:
28931524
7.

Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.

Novelli EM, Kato GJ, Ragni MV, Zhang Y, Hildesheim ME, Nouraie M, Barge S, Meyer MP, Hassett AC, Gordeuk VR, Gladwin MT, Isenberg JS.

Am J Hematol. 2012 Mar;87(3):326-30. doi: 10.1002/ajh.22274. Epub 2012 Feb 8.

8.

Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Kato GJ, Gladwin MT, Steinberg MH.

Blood Rev. 2007 Jan;21(1):37-47. Epub 2006 Nov 7. Review.

9.

Intravascular hemolysis and the pathophysiology of sickle cell disease.

Kato GJ, Steinberg MH, Gladwin MT.

J Clin Invest. 2017 Mar 1;127(3):750-760. doi: 10.1172/JCI89741. Epub 2017 Mar 1. Review.

10.
11.

Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE.

Blood. 2010 Aug 5;116(5):687-92. doi: 10.1182/blood-2010-02-268193. Epub 2010 Apr 15. Review.

12.

Cerebrovascular disease associated with sickle cell pulmonary hypertension.

Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, Lehky T, Tisdale J, Gladwin MT.

Am J Hematol. 2006 Jul;81(7):503-10.

13.

Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients.

Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS.

Ann Hematol. 2010 Sep;89(9):877-82. doi: 10.1007/s00277-010-0954-9. Epub 2010 Apr 20.

14.

Hemolysis-associated priapism in sickle cell disease.

Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH.

Blood. 2005 Nov 1;106(9):3264-7. Epub 2005 Jun 28.

15.

Vasculopathy and pulmonary hypertension in sickle cell disease.

Potoka KP, Gladwin MT.

Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L314-24. doi: 10.1152/ajplung.00252.2014. Epub 2014 Nov 14. Review.

16.

The effect of hemolysis on plasma oxidation and nitration in patients with sickle cell disease.

Kupesiz A, Celmeli G, Dogan S, Antmen B, Aslan M.

Free Radic Res. 2012 Jul;46(7):883-90. doi: 10.3109/10715762.2012.686037. Epub 2012 May 3.

PMID:
22509726
17.

Priapism in sickle-cell disease: a hematologist's perspective.

Kato GJ.

J Sex Med. 2012 Jan;9(1):70-8. doi: 10.1111/j.1743-6109.2011.02287.x. Epub 2011 May 6. Review.

18.

Sickle cell disease at the dawn of the molecular era.

Abboud MR, Musallam KM.

Hemoglobin. 2009;33 Suppl 1:S93-S106. doi: 10.3109/03630260903347617. Review.

PMID:
20001639
19.

Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.

Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ.

Blood. 2007 Sep 15;110(6):2166-72. Epub 2007 May 29.

20.

Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death.

Kato GJ, Wang Z, Machado RF, Blackwelder WC, Taylor JG 6th, Hazen SL.

Br J Haematol. 2009 May;145(4):506-13. doi: 10.1111/j.1365-2141.2009.07658.x. Epub 2008 Mar 17.

Supplemental Content

Support Center